News

  • Aspira Women’s Health Announces Appointment of Two New Board Members

    Seasoned Directors further strengthen Board with decades of industry and leadership experience June 23, 2022 16:05 ET AUSTIN, Texas, June 23, 2022 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”), a bio-analytical based women’s health company focused on gynecologic disease, today announced the appointments of two seasoned Board members: Dr. Robert Auerbach and Ms. Ruby Sharma. Dr

  • Aspira Women’s Health Announces Publication of Paper Validating OvaWatch™ Algorithm in the Detection of Ovarian Cancer

    Paper published in the June online issue of JCO Clinical Cancer Informatics June 16, 2022 16:01 ET AUSTIN, Texas, June 16, 2022 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”), a bio-analytical based women’s health company focused on gynecologic disease, today announced the online publication of a paper validating its OvaWatch™ algorithm in the detection of…

  • Aspira Women’s Health Reports First Quarter 2022 Financial Results

    May 11, 2022 07:30 ET Product Revenue Increased 30% to $1.8 million; OVA1plus Volume Grew 28% to 4,819 Units New Ordering Physicians in the First Quarter Grew 47% to 603 Year Over Year Board and Leadership appointments announced Conference Call and Webcast scheduled for today, May 11th at 8:30 a.m. ET AUSTIN, Texas, May 11,…

  • Aspira Women’s Health Reports Fourth Quarter and Full Year 2021 Financial Results

    Total Revenue Increased 46% to $6.8 million; OVA1 Volume Grew 28% to 17,359 Units Exercise of option in the Harvard Dana-Farber Cancer Institute Collaboration Leadership and Board appointments implemented in First Quarter of 2022 Conference Call and Webcast scheduled for today, March 23rd at 8:30 a.m. ET AUSTIN, Texas —March 23, 2022 — Aspira Women’s…

  • Aspira Women's Health to Announce Year End 2021 Financial Results and Host Conference Call on Wednesday, March 23rd

    AUSTIN, Texas —March 15, 2022 — Aspira Women’s Health, Inc. (Nasdaq: AWH), a bioanalytical-based women’s health company, today announced that the company will report its financial results for the year ended December 31, 2021 before the market open on Wednesday, March 23, 2022. Management will also host a conference call with investors to discuss financial…

  • Aspira Women’s Health Announces Appointment of Celeste Fralick, Ph.D., to its Board of Directors Copy

    AUSTIN, Texas —Feb. 28, 2022 — Aspira Women’s Health Inc. (Nasdaq: AWH), a bioanalytical-based women’s health company, today announced the appointment of Celeste Fralick, Ph.D., to its Board of Directors, effective February 23, 2022. Dr. Fralick is an accomplished executive with over four decades of data strategy experience. She brings to the Board a broad…

  • Aspira Women’s Health Announces Appointment of Celeste Fralick, Ph.D., to its Board of Directors

    AUSTIN, Texas —Feb. 28, 2022 — Aspira Women’s Health Inc. (Nasdaq: AWH), a bioanalytical-based women’s health company, today announced the appointment of Celeste Fralick, Ph.D., to its Board of Directors, effective February 23, 2022. Dr. Fralick is an accomplished executive with over four decades of data strategy experience. She brings to the Board a broad…

  • Valerie Palmieri Elevated to Executive Chair of the Board; Nicole Sandford Appointed President and CEO

    Expanded leadership team to drive strategic partnerships, accelerate new commercial launches, and grow overall enterprise value AUSTIN, Texas —February 25, 2022 — Aspira Women’s Health Inc. (Nasdaq: AWH), a bioanalytical-based women’s health company, today named Valerie Palmieri as Executive Chair of the Board, and Nicole Sandford as President and CEO of the Company. Jim LaFrance,…

  • Aspira Women’s Health, Inc. Expands Senior Leadership Team with Addition of Mr. Michael Newton as Head of Sales and Marketing Copy

    AUSTIN, Texas — February 22, 2022 — Aspira Women’s Health, Inc. (Nasdaq: AWH), a bioanalytical-based women’s health company today announced the appointment of Mr. Michael Newton as Head of Sales and Marketing who brings to the company over twenty years of experience in the diagnostic healthcare area. In this role, Mr. Newton will be responsible…

  • Aspira Women’s Health Announces the Addition of 465,000 Covered Lives Through Medicaid Credentialing

    AUSTIN, Texas — January 31, 2022 — Aspira Women’s Health, Inc. (Nasdaq: AWH), a bioanalytical-based women’s health company, announced today that it has entered into agreements to provide its testing services to Medicaid plan members in the state of New Hampshire and Washington, D.C equaling nearly a half million covered lives.  The state of New Hampshire covers…

  • Aspira Women’s Health Appoints Minh Merchant as General Counsel

    AUSTIN, Texas —Jan. 5, 2022 — Aspira Women’s Health Inc. (Nasdaq: AWH), a bioanalytical-based women’s health company, today announced that Minh Merchant will join the Company as General Counsel and Corporate Secretary, effective Jan. 4, 2022. In this role, Ms. Merchant will lead the Company’s legal, compliance, and enterprise risk management functions, reporting to Valerie…

  • Aspira Women’s Health Executes an Agreement with Axia Women’s Health to Launch Aspira Synergy Genetics Platform

    Axia Women’s Health is one of the largest women’s health networks in the United States serving nearly half a million women a year AUSTIN, Texas —January 5, 2022 — Aspira Women’s Health Inc. (Nasdaq: AWH), a bioanalytical-based women’s health company, announced today that it has entered into a commercial enterprise agreement with Axia Women’s Health,…

  • Aspira Women’s Health Announces Fourth Quarter Operational Metrics and Provides Updates on Its OvaWatch and EndoCheck Programs

    Fourth quarter OVA1 volume grew 23.4% to 4,750 units Plans underway for staged launches of EndoCheck and OvaWatch AUSTIN, Texas —Jan 5, 2022 — Aspira Women’s Health Inc. (Nasdaq: AWH), a bioanalytical-based women’s health company, today announced preliminary fourth quarter operational results and provided a corporate update. Operational Metrics Update OVA1® volume in the fourth…

  • Aspira Women’s Health Reports Third Quarter 2021 Financial Results

    Total Revenue Increased 34% to $1.67 million; OVA1 Volume Grew 19% to 4,281 Units Successful completion of Proof of Concept with Harvard Dana Farber Cancer Institute Collaboration Achieved Over 194 Million Covered Lives for OVA1 Conference Call and Webcast Today at 8:30 a.m. ET For a link to a pdf of this press release please…

  • Aspira Women’s Health Inc. to Report Third Quarter 2021 Financial Results on November 10

    AUSTIN, Texas — November 1, 2021 — Aspira Women’s Health, Inc. (Nasdaq: AWH), a bioanalytical-based women’s health company, today announced that it will report financial results for the third quarter ended September 30, 2021, on Wednesday, November 10, 2021, before the market open, followed by an investor conference call and webcast at 8:30 a.m. Eastern…

  • Genoox and Aspira Women’s Health Inc. Partner to Develop and Deliver Data-Driven Insights to Advance Women’s Health

    This partnership will expand on the information currently available to establish and improve advanced testing to accurately diagnose complex diseases found in women. For a PDF version of this press release, click here. Palo Alto, CA and Austin, TX, US (October 7, 2021) – Genoox, the world’s largest community-driven genomic data platform, and Aspira Women’s…

  • Aspira Women’s Health, Black Women’s Health Imperative Lead Congressional Briefing

    Call to Action for Congress to Drive Immediate Progress in Conquering Ovarian Cancer For a full pdf of this press release please click here To watch a replay of the briefing: https://www.youtube.com/watch?v=hfsrNE3P28U Austin, TX – September 30, 2021:  Aspira Women’s Health Inc (“Aspira”) (Nasdaq: AWH) together with the Black Women’s Health Imperative participated in a…

  • Aspira Women’s Health Executes Four Aspira Synergy Technology Transfer Agreements

    Aspira Women’s Health has entered into partnership agreements with two of the largest U.S.-based women’s health networks and two independent U.S. laboratories. For a pdf of this press release please click here AUSTIN, Texas —SEPTEMBER 29, 2021 — Aspira Women’s Health Inc. (Nasdaq: AWH), a bioanalytical-based women’s health company, announced today that it has exceeded…

  • Aspira Women’s Health Kicks Off Ovarian Cancer Awareness Month by Further Establishing Itself as a Thought Leader in Ovarian Cancer

    Signals Call to Action for Immediate Progress in Conquering Ovarian Cancer For a PDF version of this press release, click here. Austin, TX – September 9, 2021: Heralding the beginning of Ovarian Cancer Awareness Month, Aspira Women’s Health, Inc (“Aspira”) (Nasdaq: AWH) will ring the closing bell at NASDAQ on Thursday, September 9, 2021 to…

  • Aspira Women’s Health Reports Second Quarter 2021 Financial Results

    For a PDF of this press release, including balance sheets click here. Total Revenue Increased 141% to $1.8 million; OVA1 Volume Grew 85% to 4,553 AccessionsNew Publication Demonstrates OVA1 Superiority to Standard of CareExpanded Access of OVA1 Through AIM Specialty Health Conference call scheduled for today, August 12 at 4:30 p.m. ET AUSTIN, Texas — August…

  • Aspira Women’s Health Inc. to Report Second Quarter 2021 Financial Results on August 12

    Conference Call scheduled for Thursday, August 12th at 4:30 p.m. ET For a pdf of this press release please click here AUSTIN, Texas — July 27, 2021 — Aspira Women’s Health, Inc. (Nasdaq: AWH), a bioanalytical-based women’s health company, today announced that it will report financial results for the second quarter ended June 30, 2021 on…

  • Aspira Women’s Health Inc. Announces Coverage for OVA1® in the AIM Specialty Health Laboratory Medicine Clinical Guidelines

    AIM is a member of the Anthem Blue Cross Blue Shield family of companies which promotes optimal care through use of evidence-based clinical guidelines and real-time decision support for both providers and their patients. AIM is a wholly owned subsidiary of Anthem, Inc., serving more than 50 million members across 50 states, D.C. and US…

  • Aspira Women’s Health Releases Analytical and Initial Clinical Validation Performance for OVASight at ASCO 2021

    For a PDF version of this press release, click here. Data demonstrates the performance of OVASight in a low prevalence population-89% Specificity, 91% Sensitivity and a Negative Predictive Value of 99.6%for the management of suspected Benign Pelvic Masses AUSTIN, Texas; June 3, 2021 – Aspira Women’s Health Inc. (Nasdaq: AWH), a bioanalytical-based women’s health company focused on…

  • Aspira Women’s Health Inc. to Participate in the William Blair Growth Stock Conference

    For a PDF of this press release, click here. AUSTIN, Texas — May 19, 2021 — Aspira Women’s Health, Inc. (Nasdaq: AWH), a bioanalytical-based women’s health company, today announced that management will participate in and present at the William Blair Growth Stock Conference on June 1-3, 2021. Details for the event are below: William Blair…

  • Aspira Women’s Health Reports First Quarter 2021 Financial Results

    Conference call scheduled for today, May13 at 4:30 p.m. ET For a PDF of this press release, click here. AUSTIN, Texas — May 13, 2021 — Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on gynecologic disease, today reported its financial results for the first quarter ended, March 31, 2021. “We…